Stephen Hughes
Psychiatry · Birmingham, ALNPI 1710185400
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $630,941 of the $682,684 with a category attached, or 92.4%. 14 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 39.4% of the total. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 905 payments — averaging $754.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$269K
- Otsuka America Pharmaceutical, Inc.$223K
- Alkermes, Inc.$115K
- AbbVie$63K
- Indivior Inc.$9K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $2K from 8 others
What the payments were for
- Consulting fees$12,1662%
- Speaking & faculty fees$630,94192%
- Travel & lodging$16,7752%
- Food & beverage$22,1103%
- Education$6920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 352 | $269,083 |
| Otsuka America Pharmaceutical, Inc. | 273 | $222,636 |
| Alkermes, Inc. | 164 | $115,271 |
| AbbVie(2 entities) | 78 | $62,523 |
| Indivior Inc. | 16 | $9,375 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,840 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $862 |
| Sunovion Pharmaceuticals Inc. | 3 | $339 |
| Avanir Pharmaceuticals, Inc. | 2 | $216 |
| Lundbeck LLC | 3 | $152 |
| Tris Pharma Inc | 1 | $123 |
| Neurocrine Biosciences, Inc. | 1 | $117 |
| Johnson & Johnson | 1 | $100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$262,904
- ARISTADA$189,943
- ABILIFY MAINTENA$155,522
- AUSTEDO$107,318
- UZEDY$97,157
- REXULTI$66,407
- VRAYLAR$61,476
- Austedo XR$58,912
- ARISTADA INITIO$47,087
- ABILIFY ASIMTUFII$45,260
- PERSERIS$9,279
- LATUDA$240
- NUEDEXTA$125
- Dyanavel XR$123
- INGREZZA$117
- ABILIFY MYCITE$108
- INVEGA TRINZA$100
- INVEGA SUSTENNA$100
How this compares
$682,684 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 56 | $543,375 |
| Abilify MaintenaAripiprazole | 116 | $304,255 |
| Abilify AsimtufiiAripiprazole | 55 | $301,788 |
| Austedo XrDeutetrabenazine | 30 | $265,700 |
| UzedyRisperidone | 61 | $223,715 |
| LybalviOlanzapine/Samidorphan Malate | 120 | $189,723 |
| Invega SustennaPaliperidone Palmitate | 51 | $173,180 |
| RexultiBrexpiprazole | 95 | $144,530 |
| AristadaAripiprazole Lauroxil | 38 | $131,961 |
| VraylarCariprazine Hcl | 57 | $101,286 |
| Clozapine | 275 | $27,875 |
| VivitrolNaltrexone Microspheres | 13 | $21,224 |
| Olanzapine OdtOlanzapine | 99 | $12,332 |
| TrintellixVortioxetine Hydrobromide | 22 | $11,372 |
| Haloperidol Decanoate | 89 | $5,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $269,083 | $1,032,790147 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $222,636 | $750,573266 claims |
| Alkermes, Inc.Lybalvi, Aristada, Vivitrol | $115,271 | $342,908171 claims |
| Johnson & JohnsonInvega Sustenna | $100 | $173,18051 claims |
| AbbVieVraylar | $62,523 | $101,28657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Birmingham
- Armand SchachterBirmingham$758K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Richard SheltonBirmingham$79K
- Melissa KarrhBirmingham$51K
- Matthew MacalusoBirmingham$49K
- Santosh PillaiBirmingham$28K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
- Praveen JettyBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.